Ranibizumab in patients with dense cataract and proliferative diabetic retinopathy with rubeosis.

ABSTRACT:

Background

To evaluate the safety of ranibizumab as a surgical adjunct during cataract surgery in patients with proliferative diabetic retinopathy (PDR) with rubeosis, and to evaluate the efficacy and adverse effects of ranibizumab in treating PDR with rubeosis.

Materials and methods

Three intravitreal injections of 0.5 mg ranibizumab were administered on day-1, months-1 and -2 with cataract surgery 6-16 days after first injection. Retreatments with ranibizumab injections and pan-retinal photocoagulation (PRP) were given if recurrence or persistence of PDR was noted between months-3 and -11. Safety observation visits occurred at months-12, -18 and -24. Primary end points were incidence and severity of adverse events (AEs) that were related to both cataract surgery and treatm

SUBMITTER: Tu Y 

PROVIDER: S-EPMC3574511 | biostudies-literature | 2012 Sep

REPOSITORIES: biostudies-literature